{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:02:26Z","timestamp":1775289746672,"version":"3.50.1"},"reference-count":4,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"\n Background:<\/jats:title>\n Ceftazidime use in the neonatal intensive care unit (NICU) has increased after a cefotaxime shortage. The impact of this change is unknown. The purpose was to assess the effect of increased ceftazidime use on susceptibilities of Gram-negative organisms in the NICU.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n Retrospective study of Gram-negative isolates identified in blood, urine, cerebrospinal fluid, tracheostomy, abdominal fluid and pleural fluid cultures from a single-center NICU over a 5-year period. Duplicate cultures that occurred within 90 days were noted. Pre- and postshortage periods were defined based on cessation of cefotaxime. Third- and fourth-generation cephalosporin susceptibility rates were compared between periods, as well as rates of extended-spectrum beta-lactamase (ESBL)\n Escherichia coli<\/jats:italic>\n and\n Klebsiella<\/jats:italic>\n species.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Analysis included 666 isolates. Twelve (1.8%) were duplicate isolates that occurred after a 90-day period. The preshortage period included 464 (69.7%) isolates, and the postshortage included 202 (30.3%). No significant differences in susceptibility rates were noted when excluding duplicates. No difference in ESBL rates for\n E. coli<\/jats:italic>\n were noted between periods (3.8% vs. 4.9%,\n P<\/jats:italic>\n =1.000). No ESBL-positive\n Klebsiella<\/jats:italic>\n species were identified. A post-hoc analysis of duplicate isolates demonstrated significant lower susceptibility rates for\n Pseudomonas aeruginosa<\/jats:italic>\n to ceftazidime (risk ratio 0.58; 95% CI: 0.43\u20130.79) and cefepime (risk ratio 0.66; 95% CI: 0.51\u20130.86).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n \n Ceftazidime use did not appear to affect susceptibility rates for third- and fourth-generation cephalosporins for most Gram-negative organisms in the short-term of 1.5 years. However, susceptibility rates for\n P. aeruginosa<\/jats:italic>\n decreased when evaluating duplicate isolates. Long-term monitoring is needed to assess the true impact.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/inf.0000000000002255","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T12:32:06Z","timestamp":1543494726000},"page":"605-607","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Ceftazidime Use on Susceptibility Patterns in the Neonatal Intensive Care Unit"],"prefix":"10.1097","volume":"38","author":[{"given":"Jamie L.","family":"Miller","sequence":"first","affiliation":[{"name":"University of Oklahoma College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N.","family":"Johnson","sequence":"additional","affiliation":[{"name":"University of Oklahoma College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan P.","family":"White","sequence":"additional","affiliation":[{"name":"OU Medical System"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Neely","sequence":"additional","affiliation":[{"name":"University of Oklahoma College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Chaaban","sequence":"additional","affiliation":[{"name":"University of Oklahoma College of Medicine, Oklahoma City, Oklahoma."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Netsanet","family":"Kassa","sequence":"additional","affiliation":[{"name":"University of Oklahoma College of Medicine, Oklahoma City, Oklahoma."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Welliver","sequence":"additional","affiliation":[{"name":"University of Oklahoma College of Medicine, Oklahoma City, Oklahoma."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1542\/peds.2012-0541","article-title":"Management of neonates with suspected or proven early-onset bacterial sepsis.","volume":"129","author":"Polin","year":"2012","journal-title":"Pediatrics"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1055\/s-0032-1333413","article-title":"Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis.","volume":"30","author":"Shane","year":"2013","journal-title":"Am J Perinatol"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4103\/0971-5916.200900","article-title":"Long-term outbreak of Klebsiella pneumoniae & third generation cephalosporin use in a neonatal intensive care unit in north India.","volume":"144","author":"Banerjee","year":"2016","journal-title":"Indian J Med Res"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.42.7.1610","article-title":"Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.","volume":"42","author":"Lister","year":"1998","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201906000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:19:45Z","timestamp":1775287185000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201906000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":4,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002255","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}